Index

A

α4β2 nAChRs, 166, 168
α7 nAChR receptors, 168
α7 nAChR subunit knockout mice, 159
abstainers (nonsmokers)
  characteristics of, 22
  inclusion *versus* exclusion of, 222–223, 235, 323
  nicotine patches, 377
abstinence
  in behavioral economics effects, 420
  deficits, 350–351
  effects of, 405, 408
  event-related potential, 429
abstinence-induced craving, 438
  effects of, 405
  measurements, 403
  during smoking cessation, 441
α-bungarotoxin binding, 165, 167
ACE model, 249–250
acetaldehyde (alcohol studies), 86–87
acoustic startle reflex. *See* startle response
active avoidance, 435
acute stress mimicry of withdrawal symptoms, 448
acute tolerance, 162–163
ADA (Americans with Disabilities Act), 49
Add Health (National Longitudinal Study of Adolescent Health), 197–198, 261, 517
addiction. *See also* nicotine dependence; substance use
  clinical manifestations of, 79
  as dependence, 77
  DRD2 gene and, 32
  versus habituation, 24
  models of, 293
  versus smoking, 24
  stress and, 36
additive components, 511
adenosine knockout mice, 159
adenosine systems, in nicotine reinforcement, 159–160
*ADH1*2* alleles (alcohol studies), 86–87
ADHD. *See* attention deficit hyperactivity disorder
adipose tissue, nicotine concentrations in, 145
ad libitum (ad lib) self-administration, 415–416, 419
administration, 145–149, 418. *See also* self-administration
  in drinking water, 148, 172
  intravenous, 146, 156, 410
  oral, 148, 154, 412
adolescent(s)
  alcohol use by, 516
  cognitive control, 358, 380
  delay discounting choices, 350
  depression in, 351–352
  event-related potential, 429
  extraversion in, 349
  first mood effects, 375–376
  neuroticism in, 351, 352
  nicotine deprivation learning deficits, 436
  nicotine response in, 194–195
  novelty seeking behavior, 27, 348
  P300 amplitude in, 360
  physiological changes in, 589
  protective factors, 343
  research limitations, 367
  social influences on, 346–347, 517
  substance-use vulnerability of, 195, 199, 200–201, 212, 233–234, 261, 292–293
  transition to adulthood, 195
  use of genetic information by, 46–47
adolescent developmental trajectories, 189–235, 592
  age of smoking onset, 200–201
  empirically identified, 202–214
  example of, 223–233
  future research directions, 233–234
  psychopathology, 191–202, 292–293
  statistical models, 214–223
  substance use, 295–296 (*See also* substance-use comorbidity; *specific substance*)
adolescent nicotine dependence, 191–195
  animal models of, 155, 194–195
  biological vulnerability for, 100, 193–195, 200–201, 233
  future research directions, 233
  genetic studies of, 86, 264–266, 342
  individual symptoms of, 192
  measurement of, 192, 230–231, 264
  time and exposure required for, 192–193
  withdrawal symptoms, 192
adolescent smoking, 371
  antisocial behavior and, 200, 202, 211, 232
  environmental influences on, 196–197
  ethnic differences in, 213–214, 279

gender differences in, 196, 199, 260, 263–264, 342
gene-environment interactions in, 197–200, 259
genetic research on, 195–200, 259–269
heterogeneity in, 190, 233
as indicator of adult nicotine dependence, 230–231
latency between cigarettes, 371
molecular genetic studies of, 198–199
parental smoking and, 196–197, 200
peer smoking and, 197
prevalence of, 191
twin studies of, 196, 259–262
adolescent smoking initiation, 191
age range in, 261–262
heterogeneity of, 196, 201–202, 233
progression to dependence, 341
genetic studies of, 263–264
rate of acceleration, 201–202
psychosocial factors, 200, 202, 211
risk profile, 211–212, 232
shared environmental factors in, 260–261, 264, 280
adoption studies, 196, 279
ADRA1A gene, 42
adulthood, transition to, 195
adult nicotine dependence, adolescent smoking indicators of, 230–231
adult-onset events, 100
adult smoking phenotype, limitations of, 190
advertising
costs of, 21
in movies, 7, 20, 523
novelty seeking as response to, 348
protobacco, 7, 20, 30, 348
smoking index variable and, 30
aerosols, nicotine, 147
affective coping, 112–113
affective response, 373–376
future research directions, 456
physiological measures of, 377–378, 445–446
regulation of, 358, 403, 443–449
affiliation/empathy system, 362
African Americans
adolescent smoking in, 213–214
genotypes linked to dependence, 47
linkage study focused on, 267
age effects, 170–171
factor loadings by, 271–276
in smoking initiation assessment, 261–262, 279, 281, 322
in substance-use comorbidity, 322–323
age-gene-environment interactions, 589
age of onset, 26, 100, 371–372
developmental trajectories by, 200–201
age-related macular degeneration, 46
age-specific risk, measurement of, 35
aggregate effects in complex pathways, 541
aggression, 357
agonists (activators), 143
AHe mice, 435
AIC (Akaike Information Criterion), 274, 312
A inbred mice, 154, 165, 412, 422
A/J mice, 435
A/J×NMRI cross-bred mice, 154, 412
Akaike Information Criterion (AIC), 274, 312
alcohol use
adolescent, 516
in ATBC analysis, 496
Edwards's theory of, 82–83
Iowa gambling task as predictor, 350
nasal spray use correlated with, 373
in NHANES III analysis, 502
policies influencing, 294–295
as secondary reinforcement, 413
side effects, 86–87
tobacco use concurrent with, 98, 290, 296–298
empirical examples of, 307–323, 496, 502
health effects of, 290
modeling, 299–305
nicotine-dependence correlation, 369, 406, 411–412, 420
trajectories of, 295
*ALDH2*2* alleles (alcohol studies), 86–87
alertness, 361–362
allele(s)
identical by descent (IBD), 257, 258
variants of, 554
allele frequency, 48, 258
alpha subunits, 153
Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study (ATBC), 487, 494–497
alternative reinforcement, 417
Americans with Disabilities Act (ADA), 49
amphetamine, 412
analysis of variance (ANOVA), 215
analytic methods. *See also specific method*
developmental trajectories, 214–223
molecular genetic studies, 257–259
phenotypic research, 96–103, 113–118

anger, palliative effects on, 357
animal studies. *See also* mouse models; rat models; *specific strain or study*
  ad lib administration in, 415
  adolescent nicotine exposure, 194–195, 589
  affective regulation, 443
  dependence, 134–135
  fetal nicotine exposure, 357
  impulsivity research in, 449–450
  reward studies, 372–373
  transfer to, 350
ANOVA (analysis of variance), 215
antagonists (inhibitors)
  CB1 receptors, 160
  for mu opioid receptors, 160
  muscarinic receptors, 141
  nicotine as, 143
  for nicotine dependence, 159
anti-inflammatory effects of nicotine, 148–149
antinociception, 162
antisaccade task, 359
antisocial behavior
  adolescent smoking and, 200, 202, 211, 232
  substance use and, 292–293, 304
antitobacco stimuli, 20
anxiety
  adolescent smoking and, 201
  nicotine linkage with, 352–353, 445
anxiogenic effects of nicotine, 168
apolipoprotein E testing, 48
approach, *versus* impulsivity, 378–379
approach-related risk, 339, 346–349, 362
arousal, 378
ASN40ASP polymorphism, 407
aspartame, 412
association analysis, 258–259, 268–269, 280
assortative mating, 251, 259, 280
ATBC (Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study), 487, 494–497
ATR (Australian Twin Registry), 197, 260–261, 267
attention, 361, 378, 432–434
attentional bias, 440, 456
attention deficit hyperactivity disorder (ADHD), 354–357
  adolescent smoking and, 201, 211
  as risk factor, 350, 433
  substance use and, 292–293, 304
attrition biases, 224
Australian Twin Registry (ATR), 197, 260–261, 267
Automaticity subscale, 90–91
aversive mood symptoms, 443
avoidance-related risk, 339, 351–354, 362

B

backcrossed mice, 151
bacterial contamination, during administration, 145
BALB/cBy mice, 164–165, 430–431, 435
Barratt Impulsivity Scale, 450
Bayes factors, 552, 570
Bayesian analysis, 548–549, 570, 572
Bayesian False Discovery Probability (BFDP), 573
Bayesian Information Criterion (BIC), 310, 312
Bayesian model averaging, 117
Bayes model, 543
BAY K 8644, 167
behavior
  analysis of, 163–164
  antisocial
    adolescent smoking and, 200, 202, 211, 232
    substance use and, 292–293, 304
  drug-motivated, 404
  measurements of, 103
  nicotine and, 151–157
  phenotypes, 171
  response systems, 362
  smoking indices, 80
  substance-use comorbidity and, 322
  tolerance, 168
  traits, 344
  undercontrol, 98–99
behavioral economics, 417, 420, 454
behavioral genetics
  phenotypes in, 492
  of self-administration, 153–155
  in social context, 514–518
behavioral modeling
  methodological issues with, 247–248
  of parental smoking, 246
BFDP (Bayesian False Discovery Probability), 573
BIC (Bayesian Information Criterion), 310, 312
bioavailability of nicotine, 7, 20
biochemical indices of smoking, 80, 415
biochemical measures of self-administration, 97
biochemical pathways, 561
BioCyc, 561
biological pathways, candidate, 105
biological plausibility
  affective regulation, 443–445

attention/vigilance, 432–433
craving, 438–439
event-related potential, 427–428, 429
impulsivity, 449–450
mood effects, 374
reinforcement, 368–369, 410–414
resting EEG activity, 425–426
rewards, 372–373, 421–423
startle response, 430–431
working memory, 434–436
biological vulnerability, in adolescent nicotine dependence, 194–195
biomedical ontologies, 561
biometric factor model, 253
biometric modeling, 37–45, 86, 88–89, 514
BioPAX Ontology, 561
bitter taste, 84, 148
BKW mice, 443
blood pressure, 448–449
β2 nAChRs, 153
β2 nAChR subunit knockout mice, 159, 166
Bonferoni correction, 546, 573
brain
nicotine concentrations in, 145
stimulation, 373
upregulation in, 144
of young people, 589
brain imaging, 360
breakpoint
drug use, 418
nicotine use, 420
preferring to wait, 350
breast milk, nicotine concentrations in, 145
breeding
mice, 150–151, 411
rats, 411
Brown University Transdisciplinary Tobacco Use Research Center (TTURC), 89, 521, 526
BUB/Bn mice, 165, 412
BUB inbred mice, 154
buzz, 374

C

calcium, 136, 139–140
calcium calmodulin protein kinase II, 168
calcium channel blockers, 162, 167, 168
calcium signaling, 167–168
Canadian National Longitudinal Survey of Children and Youth, 212
cancer genetics, 50
candidate biological pathways, 105
candidate gene studies, 40–45
adolescent smoking, 342
discordant phenotype associations, 36
epigenetic differences, 37
linkage analysis, 32, 40–42, 267–268, 280–281, 589
multivariant data, 543–546
nicotine dependence, 42
prior knowledge of, 559
smoking association with, 24
SNP relationships over, 545
substance-use comorbidity, 325
trait pathways, 553
variants, 25, 35
candidate neural systems, 343–346
cannabis. *See* marijuana use
Card Arranging Reward Responsivity Objective Test, 350–351
CART (cocaine- and amphetamine-regulated transcript), 36
cases, in association analysis, 258
catechol-*O*-methyl transferase *(COMT)* gene, 269, 408–409, 430
categorical covariates, 276–278
causal contingent common (CCC) pathway model, 253, 263, 278–279
causal differences between groups, 492
causal paths
phenotypic research, 102, 107–110
sensitivity to, 105
smoking as, 352
types of, 111–113
CBA mice, 435
CB1 knockout mice, 160, 422
C57BL/6 inbred mice
conditioned place preference in, 159, 422
dose-dependent effects, 165
fear conditioning in, 169, 432
five choice serial reaction time task in, 433
nicotine consumption, 155, 159
nicotine-dependence risk, 161
nicotine effects in, 435
novelty-seeking behavior in, 156
oral self-administration in, 412–413
prepulse inhibition in, 430–431
strain comparisons, 153–154, 164–165
in tolerance, 167
C57BL/10 mice, 435

C57BR/cd mice, 435
CCC (causal contingent common) pathway model, 253, 263, 278–279
CCK gene, 269
CD-1 mice, 443
CellDesigner, 561
cell signaling, 161, 167–168
Center for Antisocial Drug Dependence, 260
Centers for Disease Control and Prevention, 498
central nervous system (CNS), 344, 348, 353, 354
centroid. *See* mean
chain smoking, 37
children
  effortful control in, 358
  secondhand smoke from parental smoking, 246
  self-control in, 344
  sleep problems in, 357
  smoking by, 371
children of twins (COT) design, 251–252, 279, 511
C3H inbred mice
  dose-dependence, 165
  nicotine effects in, 431, 435
  oral self-administration, 412
  strain comparisons, 154, 164–165
  tolerance in, 162
chippers (light smokers)
  adolescent, 213, 232
  delay discounting, 350
  genetic factors and, 29
  versus heavy smokers, 43, 81, 83–84, 90, 94
  prevalence of, 193
choice procedure, 369–370, 416, 419–420
cholecystokinin *(CCK)* gene, 269
Christchurch, New Zealand (CNZ) study, 266
CHRNA2 gene, 42, 376–377
CHRNA3 gene, 376–377
CHRNA4 gene, 268, 407–409, 412
CHRNA5 gene, 342, 376–377
CHRNA7 gene, 408, 409, 428
CHRNA5-A3-B4 haplotypes, 100, 407
CHRNA5-CHRNA3-CHRNB4 nicotinic receptor genes, 43
CHRNB2 gene, 268, 407, 408, 409
CHRNB3 gene, 342
CHRNB3-CHRNA6 nicotinic receptor locus, 43
chronic exposure, 405, 449
chronic smoker endophenotypes, 403, 404–406
  affective regulation, 443–449
  cognitive control, 432–438
  craving, 438–443
  electrophysiological measures, 425–432
  future research directions, 452–457
  impulse control, 449–452
  investigation rationale, 406–410
  motivational mechanisms, 410–424
  summary/conclusions, 457–458
chronic tolerance, 163
CIDI (Composite International Diagnostic Interview), 81
cigarette(s)
  availability of, 99
  consumption of, 4, 20
  design of, 7, 20
  pricing of, 20, 21, 520
  vendor locations, 521, 522
Cigarette Dependence Scale, 79n
Cigarette Evaluation Scale, 423
cigarettes per day (CPD)
  in ATBC analysis, 496
  with *CYP2A6* gene variants, 418
  delay discounting correlation, 452
  as dependence measure, 79, 80
  in factor analysis, 88–89
  in NHANES III analysis, 502
  nicotine metabolism and, 406
  predictive value of, 80
  recall reliability, 26–27
  as smoking cessation predictor, 81, 413
  in TUS-CPS analysis, 498, 499
cigarettes per month, 91
class extraction, model misspecification related to, 222
classic dependence criteria, 84, 86
classification bias, 493
class I–IV phenotypes, 28–31
class membership, for familial resemblance, 256–257
clinical preventive services, 4
Clinical Research Support System, 415
cluster analysis
  developmental trajectories, 211, 217–223
  discrete *versus* continuous phenomena in, 219
  static *versus* dynamic, 219–220, 232
  within-class variability in, 220–221, 233
CNS (central nervous system), 344, 348, 353, 354
CNZ (Christchurch, New Zealand) study, 266
cocaine, 374, 456–457
cocaine- and amphetamine-regulated transcript (CART), 36
coexpression of receptors, 141, 142

COGA (Collaborative Studies on Genetics of Alcoholism), 266
cognition changes, 163–164
cognitive control, 403, 424–425, 432–438
  during adolescence, 380
  alertness in, 361
  electrophysiological measures, 425–432
  as endophenotype measurements, 358, 360
  impairment, 113
  impulsivity and, 112, 378–379
  physiological basis of, 381
cognitive deficits reversal, 434–435
cognitive measures, of craving, 440
cohorts
  effects of, 515
  research models for, 519
Collaborative Studies on Genetics of Alcoholism (COGA), 266
colorectal polyps, 542
commercial testing, 50
common pathway model, 252, 270
common-vulnerability model, 291–294, 306, 315–316
communication of genetic findings, issues in, 45–50
comorbidity
  psychiatric (*See* psychiatric comorbidity)
  substance-use (*See* substance-use comorbidity)
complementary dimensions of dependence, 97
complex traits
  defining features, 31
  genetic factors in, 35
  genome-wide association studies for, 46
  multiple determinations of, 22
  replication difficulties, 45
  sensitive genetic measures, 341
  similarity of, 24–25
Composite International Diagnostic Interview (CIDI), 81
compulsive smoking, 80
computational symbolic theory, 559–560
COMT gene, 269, 408–409, 430
concurrent choice procedure, 416
conditional independence, 256
conditional triggers to smoke, 588
conditioned place preference (CPP)
  biological plausibility of, 372–374, 421
  in mice, 157–158, 161, 422
  in rats, 423
conditioning, contextual, 163–164
conduct disorder
  adolescent smoking and, 201, 211, 232
  definition of, 357
  substance use and, 292–293, 304
confounding factors, 32
consensus, across indicators, 77
constitutional hypothesis, 24
construct
  definition of, 75
  emerging, 520
  proximal, 522
  refinement of, 25–27
construct properties, 75
construct validation, 33, 34, 35, 75–78
consumption level
  during adolescence, as indicator of adult dependence, 230–231
  adolescent nicotine dependence and, 193
  assessment of, 415, 418
contamination, during administration, 145
context-sensitive physiological measures, 363
contextual conditioning, 163–164
contingency table, smoking-drinking, 313, 315–316
contingent factors, 247
continuant, 541, 559
continuous factors, 256
continuous-level information, for behavioral modeling, 247
continuous performance task (CPT), 362, 378, 433
continuous phenomena, *versus* discrete phenomena, 219
control, endophenotype measures of, 357–362
control-related risk, 339, 354–357, 362
controls, in association analysis, 258
copy-number variation, 36
core criteria, 76, 77
core dependence dimension, 87–95
core factors, 97, 168
core strategy, 510
cortisol, 447
cosegregation of smoking behaviors, 24
cost(s)
  genetic testing, 50
  smoking cessation, 593
  tobacco use, 4, 21
COT (children of twins) design, 251–252, 279, 511
cotinine
  biological activity of, 148
  clearance factors, 39–40

as nicotine by-product, 406
covariance, 32, 95–96, 341–342
in latent growth curve models, 254–255
in structural equation modeling, 248, 250
CPD. *See* cigarettes per day
CPP. *See* conditioned place preference
CPT (continuous performance task), 362, 378, 433
craving, 438–443
abstinence-induced (*See* abstinence-induced craving)
in adolescents, 192
cue-induced (*See* cue-induced craving)
dopaminergic systems associated with, 111
effects of, 405
measurement of, 403, 439–440
Craving subscale, 90–91
CREB activation, 160–161
CREB mice, 422
critical constituents, 25
cross-cultural differences, 515–516
cross-sectional studies, of substance-use comorbidity, 291
cross-species analysis, 348
cue(s)
in animal studies, 411
relapse, 99
reward signaling, 350
cue-induced craving, 438–439
with dependence, 441–443
effects of, 405
future research directions, 456–457
measurements, 403
physiological basis of, 111, 588
procedures to elicit, 440–441
research limitations in, 456
cue-self-administration response, 94
cultural transmission
adolescent smoking and, 198
effects of, 515
as environmental factor, 21
phenotypic, 251
research models for, 519
twin studies of, 262
cumulative effects, of pathogens, 103
cumulative risk, measurement of, 35
CYP2A6 gene
adolescent smoking and, 199
analysis of, 554, 555
association analysis of, 268
coding for, 408–409
mood effects with, 376
in nicotine metabolism, 22, 39–40, 149, 342, 406
in smokers, 413
variants in, 371, 418
Cyp2a5 gene variants, 149, 155, 413
CYP2B6 gene, 39
CYP2D6 gene, 39
Cys-Cys pairs, 136
cytochrome P-450 (CYP) system, 268

D

danger-alarm responses, 353, 354
data-mining techniques, 541–542
data sets
ATBC analysis, 495
NHANES III analysis, 500–501
smoking cessation analysis, 493–494, 494
TUS-CPS analysis, 498
DAT/SLC6A3 (dopamine transporter protein), 268
DBA/2 inbred mice
conditioned place preference, 422
dose-dependent effects, 165
IV self-administration, 156
nicotine consumption, 159
nicotine effects, 435
oral self-administration, 412
prepulse inhibition in, 430–431
strain comparisons, 153–154, 164–165
tolerance in, 162, 163
DDC (DOPA decarboxylase), 269
definition variables, in structural equation modeling, 248
dehydroepiandrosterone (DHEA), 447
delay discounting
definition of, 348
in impulsivity, 349, 449, 450–452
physiological basis of, 379
study subjects for, 350
deleterious effect prediction, 554
dependence. *See also* nicotine dependence
addiction as, 77
core features of, 592
definition of, 75
distal measures of (*See* distal measures)
maintenance of, 598
model evaluation of, 78
patterns, 94

severity with comorbidity, 98
study of, 24
depression, 351–352
nicotine amelioration and, 443
smoking association with, 444
subthreshold, 352
desensitization, 146
developmental pathways, 100, 589
impact on trajectory study, 222
developmental psychopathology, 191–202, 292–293
developmental trajectories. *See* adolescent developmental trajectories
DHβE, 159, 169
DHEA (dehydroepiandrosterone), 447
diabetes mellitus, 46
Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria
adolescent smoking, 192, 264
attention deficit hyperactivity disorder, 356
dependence, 37–38, 40, 81, 86
poor agreement with FTND, 25–26
scales in, 79
substance-use disorder, 291
as syndromal medical model, 80–81
diagnostic criteria, heritability of, 30, 38
diagnostic inferences, 77
Diagnostic Interview Schedule (DIS), 501
diary prompts/responses, 527, 528–529, 530
Digit Span test, 433
diltiazem, 168
direct drug infusion, 152–153
direct-to-consumer marketing, 50
DIS (Diagnostic Interview Schedule), 81, 501
disadvantaged youth, 520
discrete phenomena, *versus* continuous phenomena, 219
discrimination, against nicotine dependence, 46–47, 49
discriminative validity, 77
discussion groups (OBO Foundry project), 560
Disease Ontology (DO), 560
disease risk, 541, 550
disinhibition, common trait of, 292–293
disorder markers, 107
dispositional tolerance
acquisition of, 162
versus behavioral tolerance, 164
in tolerance, 168
distal influence, *versus* proximal influence, 519–522
distal measures
agreement among, 88
early *versus* mature states, 74
genetic mapping, 78–81, 86–87, 103–105
versus proximal measures, 516
distress tolerance, 448
distributional assumptions
in growth curve models, 255
in structural equation modeling, 249
DNA methylation, 36
DNA sequences analysis, 554
DO (Disease Ontology), 560
DOPA decarboxylase (DDC), 269
dopamine
in attention deficit hyperactivity disorder, 356
attention-vigilance associations with, 434
impulsivity linkage with, 451–452
inactivation of, 430
mesotelecephalic, 171
midbrain circuits, 348, 349, 350
in nicotine binding role, 406–407
in nicotine dependence, 43, 410
receptors, 156, 343
regulation of, 540
reinforcement role of, 374, 407
reward pathways, 342, 349, 352
signaling, 160
dopamine β-hydroxylase (DβH), 269
dopamine hypothesis of dependence, 588
dopaminergic neurons, in ventral tegmental area, 588
dopaminergic systems
adolescent smoking and, 198–199, 201
association analysis of, 268–269
craving associated with, 111
dopamine transporter protein (DAT/SLC6A3), 268
dopamine transporter *(SLC6A3) *9*-repeat allele, 441
dose of nicotine, 161, 165
differences in, 367, 416
distribution of, 370
standardization, 152
dose-response curve, 162, 444
double variant haplotype, 545
downregulation, 144–145, 588
downstream processes, 81–82, 106
DRD4 (dopamine receptor), 268
DRD5 (dopamine receptor), 268
DRD4 exon III polymorphism, 199

DRD2 gene, 409
addiction association with, 32
coding for, 408
commercial testing for, 50
dependence association with, 407
in craving, 441
variants, 198
*DRD4*7*-repeat allele, 376
drinking. *See* alcohol use
drinking-water administration, 147–148, 172
drug addiction. *See* addiction; substance use; *specific drug*
drug-motivated behavior, 404
drug response comparison, 490–492, 491
DSM. *See Diagnostic and Statistical Manual of Mental Disorders* criteria
dual-trajectory model, of smoking-drinking trajectories, 315–316
dynamic clustering
versus static clustering, 219–220, 232
within-class variability in, 220–221, 233

E

early-emergent motive, 91
early-onset smokers
risk for persistence, 200, 212–213, 230–231
substance use and, 292, 296–297, 315, 320
early smoking experiences (ESE), 375
early tobacco exposure, 101, 155
ecological momentary assessment (EMA), 255, 525
economic deprivation, 520
educational attainment, adolescent smoking and, 227–228, 232
Edwards's theory of alcohol dependence syndrome, 82–83
EEA (equal environments assumption), 516–517
EEG (electroencephalogram), 354, 403, 425–427
effortful control, 358
elasticity of demand, 417
elation, 374
electroencephalogram (EEG), 354, 403, 425–427
electromyography (EMG), 431
electrophysiological measures, 378, 425–432
EMA (ecological momentary assessment), 255, 525
EMG (electromyography), 431
empirical-Bayes approach, 549, 551
empirical search strategies, 117
employment discrimination, 49
employment status, of hard-core smokers, 35
encoding prior knowledge, 571
endogenous cannabinoid systems, 159, 160
endogenous enkephalin system, 160
endogenous event-related potentials (ERPs), 427
endophenotypes, 5, 408–410
caveats, 110–111
characteristics of, 107–110
in chronic smokers (*See* chronic smoker endophenotypes)
conceptual issues, 381–383
criteria, 413
disorders associated with, 106
future research directions, 455–457, 594
gene linking in, 347, 409
measurement of, 349–351, 353–354, 355, 357–362
motivational effects, 452, 454–455
in network models, 558
nicotine dependence, 409, 453
phenotypes associated with, 5, 33–34
pre-exposure risk, 340–347
in psychiatric genetics research, 25
replicability of, 27
transitional, 107, 108, 200, 233
types of, 340
enhanced clearance. *See* dispositional tolerance
entities, 541, 559, 560
environmental factors, 99–103. *See also* social context; *specific factor*
adolescent smoking, 196–197
comorbidity, 99
cue-induced craving, 438–439
enrichment, 36
in experimentation, 31
gender differences in, 38
gene expression variation from, 36–37
genetic factors in, 35, 515
importance of, 29
linkage analysis, 258
measurement of, 35
in nicotine dependence, 22, 23
nicotine use, 158
relative contribution of, 30
in smoking decline, 20
substance use, 294–295
twin studies, 251, 262, 279, 280
environmental pathogens, 5, 25, 35

epidemiology, 31–37
  future research in, 594
  genetic, 257
    extended, 250–252, 262–269, 279, 280
  hierarchical modeling in, 570–571
  perspectives from, 514
  phenotypic definitions in, 493
  public health outcomes in, 492
  triangle, 513
epigenetics, 36
epistasis, 32–33
epistemology, 74, 77
equal environments assumption (EEA), 516–517
equifinality, 191, 220
ERPs (event-related potentials), 403, 427
ESE (early smoking experiences), 375
ethanol, 412. *See also* alcohol use
ethnic differences, in developmental trajectories, 213–214, 279
etiological architecture, 510–511, 515–518, 519, 527, 530
etiology
  diverse, 82, 106
  matrix of, 509
  of phenotypic assay, 83
  of symptoms, 78
euphoria, 374
Event Ontology (EVO), 560
event-related potentials (ERPs), 403, 427
EVO (Event Ontology), 560
exchangeable classes, 551
excitatory tone, 141
executive function
  cognitive control and, 379
  definition of, 361
  nicotine dependence and, 34
Executive Order 13145, 49
exogenous event-related potentials (ERPs), 427
experimental design, basics of, 149–150
experimentation
  influences on, 31
  progression from, 30
exposure model, 365
extended structural equation modeling (XSEM), 249
extended twin family studies, 250–252, 262, 279, 280
extra-nicotinic mechanisms, 156–157
extraversion, 346, 348–349
extreme group membership, 96, 97
extreme groups
  alternatives to, 116–118
  constructing, 114–116
eyeblink response, 448

F

factor analysis, 37–38, 265
  consistency, 88
  correlation among, 80, 87
  DSM-IV correspondence with, 103
factor loadings, 271–278
factor mixture model (FMM), 256
factor models, 256
Fagerström Test for Nicotine Dependence (FTND), 79–80
  as assessment tool, 405
  dependence criteria, 37–38
  FTQ as precursor to, 24
  linkage analysis, 40–42, 589
  poor agreement with *DSM,* 25–26
  reliability and validity of, 26, 79–80
  scales in, 79
  visuospatial attention association with, 434
Fagerström Tolerance Questionnaire (FTQ), 79–80
  for adolescent smoking, 192, 230–231, 264
  as physical dependence measure, 79
  startle response inconsistency, 448
  in susceptibility loci mapping, 24
  test-retest reliability, 26
false discovery rates (FDRs), 542, 546, 570, 573
false positive reports, 570
familial resemblance, class membership for, 256–257
family-based studies
  design of, 518
  ecological momentary assessment in, 526–527
  heritability documentation, 28–29
  new methodologies in, 521
family dysfunction scores, 33
family environment, adolescent smoking and, 196–197
family history analysis, example of, 225, 230, 232
fast-ionotropic nicotinic receptors, 136
FDRs (false discovery rates), 542, 546, 570, 573
fear conditioning, 169, 432, 435
fear responses, 353, 354
feeder stream influences, 81–82, 106

female smokers. *See also* gender differences
adolescent, 343
blood pressure changes in, 448
nicotine-dependence factors, 37, 38, 99
OPRM1 gene in, 419
statistics on, 21
twin studies, 515, 517
fetal nicotine exposure, 357
FHS (Framingham Heart Study), 266
final common pathway, 82, 93, 106
finite mixture model, 256
Finnish Twin Registry, 262
Finn Twin16-25 study, 307–323
methods, 307–310
results, 310–323
first experience with smoking. *See* initial sensitivity
first-stage estimates, 572
Fisher, Ronald Aylmer, 22, 24
five choice serial reaction time task (5CSRTT), 432
five-class solution, example of, 226
fixed effects, 215–216
flunarizine, 168
FMM (factor mixture model), 256
focused interaction testing framework, 542
forced choice procedure, 416
formal model, 541, 559
Fosb knockout mice, 161
Foundational Model of Anatomy, 560
four-point Likert scale, 375
Framingham Heart Study (FHS), 266
F344 rats, 423
FTND. *See* Fagerström Test for Nicotine Dependence
FTQ. *See* Fagerström Tolerance Questionnaire
future research. *See also specific topics*
crosscutting issues, 595–596
implications of, 588–591
understanding, 588–596

G

γ-aminobutyric acid (GABA), 157, 406–407
γ-aminobutyric acid receptors, 43
GABA (γ-aminobutyric acid), 157, 406–407
GABAergic interneurons, 142
gateway theory of substance use, 292
GAW (Genetic Analysis Workshops), 266
gender differences. *See also* female smokers; male smokers
adolescent smoking, 196, 199, 227–228, 260, 263–264, 342
animal studies, 155, 164
cross-cultural, 515
factor loadings by, 271–276
nasal spray use, 373
nicotine-dependence factors, 38, 99
nicotine-dependence heritability estimates, 279, 281
OPRM1 gene, 419
smoking initiation, 267
startle response, 378
substance-use comorbidity, 304
twin studies, 262, 517
gender heterogeneity, 273–274, 276–278
gene(s). *See also* candidate gene studies
endophenotype linkage risks, 347, 409
in nicotine dependence, 32, 43
gene-environment interaction, 33, 515
adolescent smoking, 197–200, 259, 346
biological process initiation, 591
environmental pathogens in, 25
in etiology, 509
investigation of, 546
substance-use comorbidity, 320
underuse of, 5
gene expression, 36–37
gene-gene interaction, 199, 343, 546
gene-nicotine dependence associations, 45–46
Gene Ontology, 560
gene-pathogen relations, 100–101
general growth mixture modeling (GGMM), 308–311
generational changes, in smoking, 515
Genes, Environment and Health Initiative, 531
genetically informative designs, 527
genetically modified mice, 444
Genetic Analysis Workshops (GAW), 266
genetic architecture, 510
genetic association studies, 554, 556–559
genetic drift, 150
genetic epidemiology, 257
extended, 250–252, 262–269, 279, 280
genetic factors
acute tolerance, 162–163
conditioned place preference, 159
craving, 441
detection of, 493

in experimentation, 31
importance of, 29
measured, 4
in nicotine effects, 22, 39–40, 539
quantitative models, 512
in reinforcement, 418
relative contribution of, 30
selecting for, 96–97
genetic heterogeneity, 32
adolescent smoking initiation, 196, 201–202, 233
in developmental trajectories, 190, 233–234
gender, 273–274, 276–278
phenotypes, 341
population, 217
estimating, 218, 221–222
receptor, 139
genetic heterogeneity models, difference in fit between homogeneity models and, 274–275
Genetic Information Nondiscrimination Act (GINA), 49
genetic latent class models. *See* latent class analysis
genetic latent growth curve models. *See* latent growth curve models
genetic mapping, 73–75. *See also* phenotypic research
analytic strategies, 96–103
construct validation, 75–78
core dependence dimension, 87–95
covariation among measures, 95–96
distal measures of dependence, 78–81, 86–87, 103–105
multidimensional measures, 81–86
person factors implications in, 97–98
genetic modeling, 245–281
methodological and conceptual issues, 247–248
statistical framework for, 248–259
genetic polymorphism effects, 553–554
genetic substrata, associated with tolerance, 162
genetic testing, 46, 50
genetic variants
biological processes associated with, 109
causal, 546
disease association with, 550
evaluation context for dependence, 76
phenotypes with, 102, 106, 109, 111
pleiotropic associations of, 47–50
selection of, 101
value of, 110
gene-to-phenotype influence, 78
gene-transcription cascades, 169
genome(s)
candidate genes in, 24
data, 561
studies of, 589
genome markers, linkage analysis, 257–258
genome scan, 266–267
genome-wide association studies (GWAS), 25, 44, 269
event-related potentials, 428, 430
FTND, 42–45
genetic variant findings, 589
genotyping technologies used in, 258–259
potential of, 45–46
results from, 342
susceptibility loci identification, 407–408
genotyping
effects of variables on, 553
mouse strains, 150
P450, 39
with phase interaction, 545
phenotypes and, 560–562
technologies, 257–259
geographic information systems (GIS), 520–521
GGMM (general growth mixture modeling), 308–311
GINA (Genetic Information Nondiscrimination Act), 49
GIS (geographic information systems), 520–521
global use, 4, 21
GluR (glutamate receptor), 157, 169
glutamate receptor (GluR), 157, 169
GMM (growth mixture modeling), 202, 218, 221, 308
go/no-go task, 358–359, 451
government policies, 7, 20
effect on adolescent smoking, 193
substance use, 294–295
grant funding, 45–46
graph connectivity, 571
grouping variables, for growth curve modeling, 216–217, 232–233
group membership, stability of, across statistical models, 229–230
growth curve, nonlinear, 255
growth curve mixture modeling, 215–217, 248–249
growth mixture modeling (GMM), 202, 218, 221, 308

growth process, random effects for, 220–221
gum. *See* nicotine gum
gustatory reaction to tobacco, 75, 84
GWAS. *See* genome-wide association studies

H

habituation, *versus* addiction, 24
half-life of nicotine, 147
haplotypes
  dependence and, 100
  disease association with, 544
  double variant, 545
hard-core smokers, characteristics of, 35–36
Hardy-Weinberg equilibrium, 545
head rush, 374
health care access, disparities in, 47
health effects of smoking, statistics on, 4, 21
heart rate, 351, 354, 440, 447
Heaviness of Smoking Index (HSI)
  components of, 37, 413
  predictive value of, 80, 89–90
  scales in, 79
  zero-order correlations in, 80
heavy smokers, 93
  delay discounting, 350
  diagnostic variance in, 89
  genetic factors in, 29
  versus light smokers, 43, 81, 83–84, 90, 94
  substance use and, 296–297, 315
Heavy Smoking Index, 265
hedonic impact of nicotine, 158, 372, 424
heritability
  adolescent nicotine dependence, 86, 342
  antisocial scores, 33
  anxiety, 445
  delay aversion, 351
  dependence, 37–38, 86, 433–434
  diagnostic criteria, 30, 38
  endophenotypes, 107
  estimates, 29–30
  event-related potential, 428, 429–430
  factors in, 28–29
  gender differences in, 279, 281
  impulsivity, 451
  neuroticism, 101
  nicotine metabolism/clearance, 38–40
  P450 genotype, 39
  prepulse inhibition startle response, 431–432
  response inhibition, 359
  resting EEG, 426
  smoking cessation, 406
  smoking heaviness, 90
  withdrawal symptoms, 30
  working memory, 437
heterogeneity. *See* genetic heterogeneity
hierarchical modeling
  estimation for, 575–576
  with ontologies, 551–552
  with prior knowledge, 570
  for statistical modeling, 117
  stochastic variable selection and, 547–549, 572, 573
  weighting in, 570
high-affinity nAChRs, 156, 159
higher-order joint actions, 546
high genetic proneness, 96
hippocampal activity, 141, 142
HISTONE proteins, 36
home smoking bans, 99
homogeneity models, 271
  difference in fit between heterogeneity models and, 274–275
homogeneous population
  assumption of, 248
  for growth curve modeling, 216–217
Hooked on Nicotine Checklist, 26
Horn-Russell Scale, 34
hostility, 357, 362, 377
Household Adult Questionnaire, 501
HSI. *See* Heaviness of Smoking Index
HTR5A gene, 42
5-HTT gene, 33, 269, 441
5-HTTLPR gene, 101, 199, 409
  in adolescent girls, 343
  in affective response, 112, 446
  coding for, 408
human clinical research
  affective regulation, 444–445
  electrophysiological measures, 426
  event-related potential, 428
  impulsivity, 450
  reinforcement, 413–414
HumanCyc database, 556
human genome, similarity with mice genome, 134
3-hydroxycotinine, 406
hyperactivity, 354, 356
hypertensive rats, 449

I

IBD (identical by descent), 257, 258
ICD-10 criteria, 80–81, 192
ICR mice, 159, 162, 163
ICSS (intracranial self-stimulation), 372–373, 421
identical by descent (IBD), 257, 258
illicit substances. *See* substance use; *specific drug*
impulse control, 449–452
impulsivity, 348
  in attention deficit hyperactivity disorder, 354, 356
  clinical research, 433, 450–451
  cognitive control and, 112, 378–379
  delay discounting with, 349, 350, 449, 450–452
  heritability, 451
  measurement of, 450–451
  neural incentive system association, 346
  preclinical research, 449–450
  in response inhibition, 359
incubation effect of initial exposure, 371
independent pathway model, 253
Indiana University Smoking Survey, 223–233
  data analysis, 225–226
  discussion, 231–233
  measures, 224–225
  procedures, 224
  results, 226–231
individual pathways to mature state, 105, 106
"infectious disease" model, 522
inflammation masking, 145
inhibitors. *See* antagonists
inhibitory interneurons, 141, 142
initial exposure response measures, 339
initial sensitivity, 27, 363–364
  future research directions, 380–381
  innate sensitivity, 364–368
  other responses, 373–380
  reinforcement, 368–372
  rewards, 372–373
innate sensitivity, 364–368
instrumental learning, 158
insurance companies, genetic testing and, 49
integrative model of nicotine dependence, 22, 23
integrative theory of triadic influence, 293
intercept, distribution of, 219, 306, 310
intercept models, initiation-based, 322
intermediate phenotypes, 341, 342. *See also* endophenotypes
International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) criteria, 80–81, 192
interpersonal dynamics, 517, 522–525
interval level, 247
intracranial self-stimulation (ICSS), 372–373, 421
intrathecal administration, 162
intrauterine events, 100
intravenous administration, 146
  humans, 415
  rodents, 152–157, 410–412
in utero nicotine exposure, 357
inveterate smokers, 87
ion-channel receptors, 143
Iowa gambling task, 350
IRT. *See* item response theory
item difficulty, 270
item response theory (IRT), 254
  empirical example of, 269–279
  versus sum score approach, 278

J

Jarvik, Murray, 24
journal publishing requirements, 45–46

K

kinship model, twin studies extended to, 250–252, 262, 279, 280
k-means clustering, 217
knockout mice, 159, 160, 161, 166, 422
Kraepelinian approach to diagnosis, 291
Kyoto Encyclopedia of Genes and Genomes, 561

L

laboratory-based measurements
  attention deficit hyperactivity disorder, 356
  consumption, 418
  endophenotypes, 349–351, 353–354, 357–362
late emergent symptoms, 90–91
latency to first puff, 415
latent class analysis, 80, 92, 98, 248–249, 256–257, 266, 280
latent class growth analysis (LCGA), 218, 226–229, 248–249
latent growth curve (LGC) models, 254–256, 266, 280

association data integrated into, 259
substance-use comorbidity, 306, 308, 321
latent phenotype model, 252, 270
latent profile modeling, 90–91
latent trait, 270
latent variables, 77, 248, 256
substance-use comorbidity, 306, 321, 324
LCGA (latent class growth analysis), 218, 226–229, 248–249
LD (linkage disequilibrium), 543, 545–546
learning associations, 349
learning differences, 158, 169
letter cancellation task, 433
level, in latent growth curve models, 254
Lewis rats, 411, 423
LGC. *See* latent growth curve models
liability models, of smoking behavior stages, 264, 280
lifetime regular smoking, definition of, 29
ligand-activated ion channels, 143
light smoking. *See* chippers
likelihood-based approaches, in cluster analysis, 217–218
likelihood ratio tests, 310, 312–313
linear growth, assumption of, 255
linear model, 116
linear regression, in structural equation modeling, 248
linear relations, 25
linkage analysis, 257–258, 266–268
candidate gene studies, 32, 40–42, 267–268, 280–281, 589
environmental factors, 258
genome markers, 24, 257–258
nicotine-dependence indices, 40–42
linkage disequilibrium (LD), 543, 545–546
Lister rats, 432–433, 444
lithium-chloride conditioned place aversion, 161
liver cytochrome P-450 enzyme CYP2A6. *See* *CYP2A6* gene
location of smoking, 527
loci segregation, 40
locomotor activity, 369, 422
logarithm of odds (LOD) score, 40–42, 258, 267
logistic regression curves, 91
Long-Evans rats, 411
longitudinal data
growth curve modeling of, 218–219, 234
on substance-use comorbidity, 291, 320
Loss of Control subscale, 90–91
low genetic proneness, 96
LPAAT-delta gene, 42
lung, nicotine concentration in, 145
lung cancer, predisposition to, 44, 50

M

macrocontextual factors, 509, 514
as moderators, 515–516
macroenvironment proximal indicators, 521–522
macular degeneration, age-related, 46
magnetic resonance imaging (MRI), 351, 439, 456–457
maintenance of dependence, 589
male smokers. *See also* gender differences
adolescent, 342, 348
blood pressure changes in, 449
nicotine-dependence factors, 37, 38, 99
OPRM1 gene in, 419
statistics on, 21
twin studies, 515, 517
manifestations of dependence, 75
Mannheim Study of Risk Children, 199
MAO. *See* monoamine oxidase
MAP3K4 gene, 42
marginalization
of smoking, 4, 21
of social groups, 47
marginal nonnormality, 221
marijuana use
early pleasurable, 374
tobacco use concurrently with, trajectories of, 296–298
modeling, 304–305
trajectories of, 295–296
marketing direct-to-consumer, 50
Markov chain Monte Carlo (MCMC) methods, 542
masking etiology, 82
masking of causal factors, 74
maternal care, 36
mature subphenotypes, 82, 110–111
maximum acute tolerance, 162, 165
maximum price assessment, 418
McGill University Study on the National History of Nicotine Dependence, 199
MCMC (Markov chain Monte Carlo) methods, 542
mean (centroid)
cluster analysis, 217
growth curve modeling, 255
structural equation modeling, 248–249

measured genetic factors, 4
measurement invariance, 247, 255, 276, 280
mecamylamine, 159
mediation
  of conditioned place preference, 161
  by endophenotypes, 107–108
  of nicotine, 160
memantine, 156, 171
memory, 379, 434–438
Mendelian randomization, 118
mesolimbic dopaminergic system, 410, 411
metabolic tolerance, 97
metabotropic glutamate receptor 5 (mGluR5), 156
methodological issues
  assessment precision, 520
  behavioral modeling, 247–248
  family-based studies, 521
  future research directions, 383–384, 594
  genetic modeling, 247–248
  innate sensitivity research, 366–368
  real-time interaction, 524–525
  research limitations, 366–368, 376, 383–384
  substance-use comorbidity, 321–323
methyllycaconitine citrate (MLA), 159
mGluR5 (metabotropic glutamate receptor 5), 156
mice. *See* mouse models
microchip analysis, 170, 258–259
microcontextual factors, 509, 514
  coding of real-time interaction, 524
  as moderators, 516–518
microsatellites, 543, 551
microsocial context, quantifying, 522–525
midbrain dopamine circuits, 348, 349
Mid-South Tobacco Family (MSTF), 267
migration levels, 516
Minnesota Nicotine Withdrawal Scale, 446
Minnesota Twin Family Study (MTFS), 196, 260, 360
mirror tracing, 448
misleading claims, 50
misspecification, model, 222
mixed models, developmental trajectories, 215
MLA (methyllycaconitine citrate), 159
model(s)
  clarification of, 559
  searching, 551
  selection of, 547
  with stochastic variable selection, 549–550, 551–552
model fit, evaluation of, 310, 312–313
modeling. *See also specific types of modeling*
  phenotype (*See* phenotype modeling)
  with prior knowledge, 570
  selection algorithm, 577–578
  uncertainties in, 546, 547, 549
model misspecification, 222
moderation of relationships, 248
modified pairwise interaction, 545
modulation
  dopamine receptors, 156
  nicotine rewards, 160
molecular genetic studies, 266
  of adolescent smoking, 198–199
  analytic framework for, 257–259
Monitoring the Future project, 299, 304
monoamine oxidase (MAO)
  in anxiety disorders, 353
  neuroticism and, 351
  in neurotransmitter breakdown, 540
monoamine oxidase *(MAOA/MAOB)* gene, 269
mood effects, 373–376, 380–381
  in ATBC analysis, 497
  measures of, 372
  of nicotine, 366
Mood Form of Diener and Emmons, 374–375, 446
morning smoking. *See* time to first cigarette
morphine, as nicotine substitute, 153
Morris water maze, 435
mortality statistics, 4, 21
motivational mechanisms, 84, 403, 408
  reinforcement, 410–420
  rewards, 420–424
Mouse Genome Informatics database, 150
mouse models, 134–135, 418
  adolescent exposure, 194–195
  behavioral changes, 151–157
  future research directions, 168–172
  nicotine administration, 145–149
  nicotine dependence, 149–151
  nicotinic receptors, 135
    customizing, 141–143
    functional diversity of, 136–141
    molecular biology of, 136
    nicotine as agonist/antagonist, 143–144
    upregulation, 144–145
  reward, 157–161
  startle inconsistency, 444
  strains, 134 (*See also* strain-specific differences; *specific strain*)
    research options with, 592
    selection of, 150–151

tolerance, 162–168
mouse-rat differences, 150
movies, smoking in, 7, 20, 523
MRI (magnetic resonance imaging), 351, 439, 456–457
MSTF (Mid-South Tobacco Family), 267
MTFS (Minnesota Twin Family Study), 196, 260, 360
multidimensional measures, of nicotine dependence, 81–86
multifinality, 191
multilevel analysis, difficulties of, 248
multiple trajectories, developmental, 191–202, 232–234
multivariate analysis
developmental trajectories, 215
latent growth curve models, 255
substance-use comorbidity, 315–316, 321
twin studies, 262–263
multivariate factor model, 252–253
multivariate normal distribution
in growth curve models, 255
in structural equation modeling, 249
multivariate normality, within-class, 221, 233
mu opioid knockout mice, 422
mu opioid receptors
in conditioned place preference, 160
in nicotine replacement therapy, 407
reward mediation, 419
in tolerance, 167, 168
muscarinic acetylcholinergic systems, 166, 168
muscarinic receptors
in aging, 170
blockading, 140–141
metabotropic, 136
muscle tension, 377–378
mutations
rate predictions, 554
for tolerance, 166
Muthén, Bengt, 218

N

nAChRs. *See* nicotinic acetylcholine receptors
Nagin, Daniel, 218
naloxone, 160
nasal spray. *See* nicotine nasal spray
National Cancer Institute, 498
National Center for Biomedical Ontology (NCBO), 561
National Comorbidity Study, 445
National Health and Nutrition Examination Survey (NHANES III), 487, 494, 500–503
National Institute of Mental Health Diagnostic Interview Schedule (DIS), 81, 501
National Institute on Drug Abuse Genetics Consortium, 43
National Institutes of Health, 531
National Longitudinal Study of Adolescent Health (Add Health), 197–198, 261, 517
National Survey on Drug Use and Health, 93
N-back task, 436
NCBO (National Center for Biomedical Ontology), 561
NDSS. *See* Nicotine Dependence Syndrome Scale
NEAD (Nonshared Environment in Adolescent Development) Project, 509, 524–525
Netherlands Twin Register, 262
Netherlands Twin Study of Anxious Depression (NETSAD), 266–267
network models, 554, 556–558
neural analysis, 349–351, 353–354, 357–362
neural incentive system, 346
neural networks modeling, 340–341
neural substrata, associated with tolerance, 162
neural systems, candidate, 343–346
neurexin 1 *(NRXN1)* gene, 43
neurobiological analysis, 348
neurobiological dependence pathways, 43
neurobiological systems, 344
neuroendocrine response, to stress, 354
neuroimaging, 360, 379–380
neuropeptide systems, 159, 160
neuroprotection, 170
neuroticism, 101, 351–353
neurotransmitter systems
in chronic tolerance, 166–167
in conditioned place preference, 159–161
New England Family Study, 526
NHANES III (National Health and Nutrition Examination Survey), 487, 494, 500–503
nicotine
administration of (*See* administration)
age-related response differences, 194–195
as agonist/antagonist, 143–144
anti-inflammatory effects of, 148–149
anxiogenic effects of, 168
behavioral changes from, 151–157
bioavailability of, 7, 20
enforcement timing, 369
in free-base form, 148

frequency of use, 4, 21, 369–371, 413, 420
hedonic impact of, 158, 372, 424
neuronal activity induced by, 43
physical changes from, 162
pre-exposure risk (*See* pre-exposure risk)
pretreatment, 420
reinforcement (*See* reinforcement)
rewards and (*See* reward)
tolerance (*See* tolerance)
nicotine aerosols, 147
nicotine-binding sites, 135, 144
nicotine choice, 369
nicotine choice procedure, 416, 419–420
nicotine cigarette choice paradigm, 419
nicotine clearance
dispositional tolerance, 162, 164, 168
genetic factors in, 39–40, 539
nicotine dependence, 20–22, 149–151
in adolescence (*See* adolescent nicotine dependence)
concurrent with substance use (*See* substance-use comorbidity)
construct refinement, 25–27
craving associated with (*See* craving)
crosscutting issues, 595–596
developmental pathways in, 589
distal measures of (*See* distal measures)
endophenotypes in, 409, 453
epidemiological concepts, 31–37
future research directions, 455–457
heritability of (*See* genetic factors; heritability)
historical perspective of, 22–25
inference of, 77
mouse models of (*See* mouse models)
phenotype (*See* phenotype(s))
progression research, 592
psychiatric disorders correlated with, 98
risk with, 375–376
smoking compared with, 87
versus tobacco dependence, 75
treatment of (*See* smoking cessation)
understanding of, 588–596
nicotine-dependence measures, 26, 28, 37–45, 73, 78, 79
adolescents, 192, 230–231, 264
example of, 225
invariance, 276, 280
Nicotine Dependence Syndrome Scale (NDSS), 82–84
abbreviated, 500
as assessment tool, 405
subscales of, 90
in TUS-CPS analysis, 498
nicotine deprivation memory deficits, 436
nicotine gum
as consumption assessment, 415
effect on EEG activity, 426
in memory effects, 435
versus placebo, 370
nicotine metabolism
association analysis of, 268
catabolism of, 149
CPD variation and, 34
CYP2A6 gene in, 39–40, 149, 342, 406, 418
in dependence risk, 22, 342
in ontology example, 562–569
pathway, 556
nicotine nasal spray
aversion with *DRD4*7*-repeat allele, 376
as consumption assessment, 415
in current smokers, 374
memory effects of, 435–436
versus placebo, 369–370
pleasurable responses to, 373
nicotine patches
effect on EEG activity, 426
in memory effects, 435
on nonsmoking adults, 377
Nicotine Pharmacokinetics Ontology (NPKO), 539, 561, 571
nicotine replacement therapy (NRT), 406. *See also* smoking cessation
nicotinic acetylcholine receptors (nAChRs), 134
association analysis, 268
as attention factor, 362
beta2-subunit *(CHRNB2),* 268
binding to, 588
blockading, 140–141, 143–144
chromosomal regions, 43, 44, 50
in chronic tolerance, 166–167
coding for, 408
customizing, 141–143
desensitization of, 146
fast-ionotropic, 136
functional diversity of, 136–141
high-affinity, 157
illustration, 409
as impulsivity mediator, 449
inactivation of, 143
inferences from, 152–153

initial sensitivity response with, 376–377
molecular biology of, 136
in nicotine binding role, 406–407
in nicotine dependence, 411
structure of, 136–138, 138
tissue-specific responses, 71, 133
in tolerance, 168
upregulation of, 135, 144–145, 588
nicotinic receptor subunits, 136–140
CHRNA5/CHRNB3 genes, 342
composition of, 139
functional variants of, 140
limiting expression, 141–143
structure of, 136, 137
nimodipine, 162, 167, 168
nitric oxide, in conditioned place preference, 161
7-nitroindazole, 161
N-methyl-D-aspartic acid (NMDA) glutamate receptors, 156
NMRI outbred mice, 154, 412, 430
nomological net, 76
noncoding DNA sequences, 554
nonlinear growth curves, 255
nonnicotinic systems, 166
nonnormality, 221
Nonshared Environment in Adolescent Development (NEAD) Project, 509, 524–525
nonsmokers (abstainers)
characteristics of, 22
inclusion *versus* exclusion of, 222–223, 235, 323
nicotine patches, 377
Northern California Twin Registry, 539, 540
novelty seeking, 155–156, 199, 348–349
by adolescents, 27
nasal spray use in, 373
neural incentive system association with, 346
in substance use, 292–293, 348–349
NPKO (Nicotine Pharmacokinetics Ontology), 539
NRT (nicotine replacement therapy), 406. *See also* smoking cessation
NRXN1 gene, 43
NRXN3 gene, 43
nutritional cancer prevention, 497

O

OBO (Open Biomedical Ontologies), 560
OBO-Edit, 561
OBO Foundry project, 560
OBO Relation Ontology, 561
observed variables, in structural equation modeling, 248
occurrent, 541, 559
oddball stimulus, 429
olanzapine, 456
ontologies, 539–541
definition of, 541, 559
development process, 560–562
discussion of, 570–574
methods, 541–543, 550–562
nicotine metabolism, 562–569
statistical approaches, 543–550
Ontology Web Language (OWL), 561
Open Biomedical Ontologies (OBO), 560
Open Source software, 561
OPRM1 gene, 409
coding for, 408
gender differences in, 419
in nicotine replacement therapy, 407
in smokers, 423
support interval proximity, 42
oral administration, 147–149, 172, 412–413
oral mucosa exposure to nicotine, 148
ordinal data, analytical framework for, 247, 255
osmotic minipump, 147
outcomes of dependence, 75
outliers, controlling for, 281
OWL (Ontology Web Language), 561
oxotremorine, 166–167

P

P3 amplitude, 294
panic disorder, 353
PANTHER Pathways databases, 556, 561
parent(s)
educational level of, 519
twin studies extended to, 251, 262, 279, 280
parental monitoring, as smoking counterforce, 22
parental smoking
adolescent smoking and, 196–197, 200, 262, 346
behavioral modeling of, 246
nasal spray non-response, 377
smoke-free home with, 523
socialization effects from, 517
parenting behavior, 342
partition variation, 270, 280
passive avoidance, 435
patch. *See* nicotine patches

path diagrams, in structural equation modeling, 248–250
pathogen modeling, 100–101, 103
PATO (Phenotype and Trait Ontology), 560, 571
Pavlovian learning, 158
PBT (problem behavior theory), 198, 292–294, 322
PDAs (personal digital assistants), 525–527
peers
  as influence, 100, 346, 517
  as smoking predictors, 523
peer smoking, effect on adolescent smoking, 197
penetrance, incomplete, 31
peripheral nervous system (PNS), 344, 348
P50 ERP, 427–428
persistence
  drug use, 417–418
  negative affect with, 447
  smoking (*See* smoking persistence)
personal digital assistants (PDAs), 525–527
personalized health care, 49–50
person factors, 97–99
PET (positron emission tomography), 439
P300 event-related potential (ERP), 359–360, 429–430
P450 genotype, 39
pharmacokinetics, 37, 39, 118, 149, 542, 590
pharmacokinetics ontology, 539, 561, 571
phenotype(s)
  assays, 83
  association of, 33
  behavioral, 171, 492
  characteristics of, 109
  components, 341
  developmental progression of, 74
  effects of variables on, 553
  as endophenotypes, 5, 33–34
  environmental, 34–36
  framework, 27–31
  genetic mapping, 96–103
  genetic variants to, 102
  genotyping and, 560–562
  heterogeneity, 341
  intermediate, 341, 342 (*See also* endophenotypes)
  of mouse strains, 150
  pathways, 23, 590
  as points in smoking trajectory, 490
  research pitfalls, 489
  stages, 109
  substance-use disorders, 316–318, 321, 324
Phenotype and Trait Ontology (PATO), 560, 571
phenotype modeling, 487, 488–492
  examples, 493–503
  methods, 492–494
  summary, 503–505
phenotypic assortative mating, 251
phenotypic cultural transmission, 251
phenotypic research, 105–106
  analytic strategies, 113–118
  causal paths, 107–110, 111–113
  caveats, 110–111
  summary, 118–119
phenylthiocarbamide (PTC) haplotype, 84
phosphatase and tensin homolog *(PTEN)* gene, 269
physical aggression, 357
physical responses to nicotine, 169
  symptoms, 26
  in tolerance, 162–163, 164–165
physiological measures of response reward, 351
physiological startle. *See* startle response
physiology
  of affect, 377–378
  of behavioral traits, 344, 345, 346
Pittsburgh Youth Study, 214
placebo, *versus* nicotine, 369–370, 420
placenta, 145
plasma nicotine levels
    with IV injection, 146
    tissue nicotine levels compared with, 145
    in tolerance studies, 163–164
pleiotropy, 32, 47–50
PNS (peripheral nervous system), 344, 348
point mutation, 444
policy interventions, 34–35
polymorphisms, 553–554. *See also* single nucleotide polymorphism
  associations with, 116
  different priors for, 571
  in dopamine reward pathway, 342
  emphasis within genes, 547
  investigation of, 546–547
  numerous, challenges of, 546–547
  perturbations from, 554
  trait variation effect of, 549
PolyPhen (polymorphism phenotyping), 554
polysubstance use, 43, 296
population
  frequency of genetic factors in, 86

for growth curve modeling, 216–217, 234
homogeneous, assumption of, 248
in latent class analysis, 256
response distribution in, 370, 373, 376–380
in structural equation modeling, 248–249
population heterogeneity, 217
estimating, 218, 221–222
Positive and Negative Affect Schedule, 374–375, 446
positron emission tomography (PET), 439
postural hypotension, 449
PPI (prepulse inhibition), 378, 403, 430–432
preclinical research. *See also* animal studies; mouse models
affective regulation, 443–444
electrophysiological measures, 425–426
event-related potential, 427–428
impulsivity, 449–450
reinforcement, 410
rewards, 421–423
precursors, class III phenotypes as, 30
predictive validity
of genetic testing, 50
of primary motives scales, 90–91
pre-exposure risk, 339, 340. *See also* smoking initiation and progression risk
endophenotypes, 340–347
future research directions, 381–385
initial sensitivity endophenotypes (*See* initial sensitivity)
preproenkephalin knockout mice, 160, 422
prepulse inhibition (PPI), 378, 403, 430–432
price-demand curve, 417
pricing, of tobacco products, 20, 21, 520
primary motive scales, as predictors, 90–93
prior covariate specification, 570–571
prior knowledge, ontologies and, 553–562
PR (progressive ratio) measures, 417–418, 420, 454
probability discounting, 450–451
problem behavior theory (PBT), 198, 292–294, 322
problem use, 196, 198, 263, 294
Profile of Mood States, 374–375, 446
programmed lapse procedure, 454
progression to smoking, 491
progressive ratio (PR) measures, 417–418, 420, 454
Project on Human Development in Chicago Neighborhoods, 520
"proof of concept" analyses, 493, 494
protective factors
in adolescents, 343
versus vulnerabilities, 87, 114
protein sequence data, 561
protobacco advertising, 7, 20, 30, 348
prototypes, of nicotine-dependence research, 27–28
proximal indicators, 509
proximal influence, 519–522
proximal measures
versus distal measures, 516
of social context, 518–527
psychiatric comorbidity, 81, 98–99
with *DSM-IV* dependence, 26, 81
empirical examples of, 496, 502
resolving, 115
psychiatric genetics research, 25, 27
psychoactive alkaloid, 22
psychological traits
approach-related risk, 346–349
avoidance-related risk, 351
control-related risk, 354–357
psychometric common factor model, 252
psychopathology
developmental, 191–202, 292–293
indices, 32
physiological basis of, 344
substance use and, 292–293, 304
psychophysiological responses
to acute stressors, 448–449
craving, 440
psychosocial factors
in adolescent nicotine dependence, 195
in adolescent smoking initiation, 200, 202, 211
PTC (phenylthiocarbamide) haplotype, 84
PTEN gene, 269
public health messages, 47
public health outcomes, 492
public settings, smoking in, 4, 20–21
putative endophenotypes, 341

Q

QSU (Questionnaire on Smoking Urges), 439
QTL (quantitative trait locus), 258
quantitative genetic models, 512, 522
quantitative trait locus (QTL), 258
quantity smoked measures, 28
Questionnaire on Smoking Urges (QSU), 439

R

racial background, 439. *See also* African Americans
racism, associated with genetic information, 47
random effects, 216
  within-class, 220–221, 233
rapid-decision context, 358
Rapid Visual Information Processing (RVIP) task, 433
rat models
  adolescent nicotine exposure in, 194–195
  alcohol/nicotine correlation, 369
  conditioned place preference in, 423
  self-administration of electrical stimulation, 421
  sensitivity in, 364
  strains, 411 *(See also specific strain)*
Reactome, 561
real-time contexts, 526
real-time interaction, 524–525
recall, 379
receptor heterogeneity, 139
recovery, from acute tolerance, 162
regression models, 248, 542, 543, 550–551, 572
regular smoking
  definition of, 29
  genetic factors in, 29–30
reinforcement, 151–152, 155–156, 366–372, 380
  alternative, 417
  in cognitive control, 349
  enhancing, 413
  genetic influences in, 418
  in initial sensitivity, 368–372
  measurement of, 414–420
  motivational mechanisms, 410–420
  secondary, 411, 413
relapse
  environmental influences in, 95
  physiological basis of, 588
  predictors of, 77, 413, 434, 442, 444–445
  time to first cigarette as predictor of, 80, 89
relations between entities, 541, 559, 560
relative measurements, 571
reliability. *See also* test-retest reliability
  of developmental trajectory research, 234
  of nicotine-dependence measures, 26, 79–80
  recall, 26–27
reliability coefficients, 79
religiosity, adolescent smoking and, 198
repeated-measures data, developmental trajectories, 215, 222
replication, of gene-nicotine dependence associations, 45–46
research findings, communication of, issues in, 45–50
research limitations
  adolescent smoking, 367
  adult smoking phenotype, 190
  ATBC analysis, 497, 504
  behavioral measures, 104
  cue-induced craving, 456
  data, 572
  distal measures, 103
  DSM, 103
  extreme groups, 114–116
  methodology, 366–368, 376, 383–384
  NHANES III analysis, 503–505
  nicotine-dependence measures, 103–104
  Nicotine Dependence Syndrome Scale, 84
  retrospective reporting, 367
  self-report measures, 367
  smoking cessation research, 454–455
  statistics modeling, 570
  tobacco dependence assessments, 95
  TUS-CPS analysis, 500, 504
  twin studies, 279–280
  Wisconsin Inventory of Smoking Dependence Motives, 85–86
residual familial factors (F), 258
residual item variances, 270
respiratory sinus arrhythmia (RSA), 361
response inhibition, 358–359
resting EEG activity, 425–427
retail tobacco outlets, 520, 521
retrospective reporting limitations, 367
reward, 157–161
  definition of, 349
  for depressed smokers, 352
  future research directions, 454–455
  immediacy over magnitude, 348, 349
  in initial sensitivity, 372–373
  measurement of, 351, 366, 372–373, 380, 423–424
  modulation of, 160
  motivational mechanisms, 420–424
  mu opioid receptor mediation, 419
  preclinical studies, 157–161, 372–373, 421–423
  signaling, 350
reward and pleasure pathways, 22
reward-discounting tasks, 350

rimonabant, 160
risk. *See also* pre-exposure risk; smoking initiation and progression risk
  age-specific, measurement of, 35
  approach-related, 339, 346–349, 362
  avoidance-related, 339, 351–354, 362
  control-related, 339, 354–357, 362
  cumulative, measurement of, 35
  disease, 541, 550
  with nicotine dependence, 375–376
  nicotine metabolism and, 22, 342
risk factors
  adolescent smoking initiation, 211–212, 232, 350, 433
  substance use, 306, 340
risk-taking behavior, by adolescents, 195, 199
RNA analysis, 142
rodent models. *See also* mouse models; rat models; *specific strain*
  adolescent nicotine exposure, 194–195
  adolescent sensitivity, 371
  intravenous self-administration, 410
  nicotine effects, 368, 435
  strain-specific differences, 418
RSA (respiratory sinus arrhythmia), 361
**RS578776* subunit gene, 43
**RS16969968* subunit gene, 43
Russell, M.A.H., 24
RVIP (Rapid Visual Information Processing) task, 433

S

saccharin, 148, 154, 159
S allele, 112, 113
sample size/followup
  in ATBC analysis, 497
  for developmental trajectory research, 234
  in TUS-CPS analysis, 498
saturated model, 547
SBML (Systems Biology Markup Language), 561
schizophrenia, 428, 443
secondary criteria of nicotine dependence, 76, 77
secondary motives scales, 92–93
secondary reinforcement, 411, 413
secondhand smoke, 20, 246
second-stage mixture model, 572
self-administration
  ad libitum (ad lib), 415–416, 419
  genetic effects on, 146
  intravenous, 146, 152–157, 410–412
  oral, 412–413
self-control, in children, 344
self-insuring firms, 49
self-report measures
  of affect, 446–447
  components of, 79
  of craving, 439–440
  ecological momentary assessment in, 525
  limitations of, 367
SEM. *See* structural equation modeling
semi-Bayes approach, 549
semistructured paradigms, 524
Sensation Seeking Scale, 377
sensitivity
  of measurements, 341
  modeling, 363–364, 364
  periodic, 96
sensitivity analysis, 570
sensory measures, 403
Sensory Questionnaire, 423
sequential process model, of substance-use comorbidity, 304
serotonin
  association analysis, 268–269
  genetic variation in, 343
  metabolism of, monoamine oxidase in, 353
  regulation of, 540
  smoking cessation and, 407
SES. *See* socioeconomic status
seven-point Likert scale, 372
shared environment effects
  in adolescent smoking, 197, 260–261, 264, 280
  twin studies, 251, 280
Shiffman-Jarvik Withdrawal Scale, 440
Shiffman Nicotine Dependence Syndrome Scale. *See* Nicotine Dependence Syndrome Scale
sibling(s)
  IBD configurations for, 257–258
  smoking epochs of, 531
  as smoking predictors, 523
  socialization studies, 517
  twin studies extended to, 251, 262, 279, 280
Sibling Partners Study, 526
sickle cell discrimination, 47
side effects
  from drinking-water administration, 172
  from intravenous administration, 146
SIFT (Sorting Intolerant From Tolerant) procedure, 554

simultaneous effect of genes, 32–33
single-factor dependence, 79n
single-factor structure, 81
single-group growth curve model, 219
single nucleotide polymorphism (SNP)
  candidate gene variants, 25
  disease association with, 544
  genotyping, 43, 257–259
  nonsynonymous coding, 554
  as reflection of underlying effects, 546
  relationships over candidate genes, 545
  relevance of, 570
  in whole-genome research, 4
situational dependence, 27
six-class solution, example of, 227–228
skin conductance, 354, 377–378
skin temperature, 440
SLC6A3 gene, 198
SLC6A4 gene, 32, 101, 112, 113
sleep problems, in children, 357
slope
  distribution of, 219
  factor loading and, 275–276
  in latent growth curve models, 254, 306, 310
129S6 mice, 430
SMOFAM (Smoking in Families Study), 267
smoke-free laws, 520
smoke-free settings, 20, 30, 523
smokeless tobacco, 147
smokers, characteristics of, 22
smoking
  bans on, 99
  decline in, 20
  developmental phenotypes (*See* adolescent developmental trajectories)
  first experience with (*See* initial sensitivity)
  frequency of, 369–371, 413, 420
  during illness, 79, 80
  nicotine dependence compared with, 87
  quantitative genetic model and, 512
  status, 28
  transition levels, 42–43, 488–490
smoking cessation
  age-related changes in, 170
  barriers to, 4–5, 46
  CHRNB2 gene in, 407
  commercial testing, 50
  comparison groups changes, 493
  data sets in, 493–494, 494
  definition of, 492
  delay discounting factor in, 350
  demand for, 21
  difficulties of, 97
  drugs for, 160
  failures in, 44–45
  FTND predictions of, 80
  future research directions, 454
  gender differences in, 38
  heritability in, 406
  monoamine oxidase decrease during, 351
  research limitations in, 454–455
  serotonin pathway and, 407
  subthreshold pretreatments, 162
  success predictors, 81, 89, 413, 434
  symptoms of, 447
  tailored, 48
smoking index variable, 30
Smoking in Families Study (SMOFAM), 267
smoking initiation, 31, 42
  adolescent (*See* adolescent smoking initiation)
  assessment of, age effects in, 279, 322
  definition of, 29
  gender differences in, 267
  linkage analysis of, 267
  versus persistence, 406
smoking initiation and progression risk, 346, 491. *See also* pre-exposure risk
  approach-related, 346–349
  avoidance-related, 351–353
  control-related, 354–357
  endophenotypic measures, 349–351, 353–354, 357–362
  future research directions, 362–363
smoking level
  measurement of, example of, 224–225
  substance-use comorbidity and, 308, 322
smoking pattern, factor analysis of, 265
smoking persistence, 29, 30, 406
  definition of, 29
  early-onset smokers' risk for, 200, 212–213, 230–231
smoking topography devices, 415, 418
SNP. *See* single nucleotide polymorphism
social context, 509, 510–511
  adolescent smoking, 193, 198
  behavioral genetics in, 514–518
  future research directions, 527–532
  proximal measures of, 518–527
  rationale for, 511–514
  substance use, 294–295

social development model, 293
socioeconomic status (SES)
  adolescent smoking and, 232
  distal to proximal influence, 519–522
  of hard-core smokers, 35
  nuanced approaches to, 519–520
socioregional influences, 515–516
"softening" of smoking, 193
software
  association analysis, 259
  item response theory, 270
  linkage analysis, 258
  ontology, 561, 562
Sorting Intolerant From Tolerant (SIFT) procedure, 554
SourceForge Web site, 562
species-specific responses, 134
specific-factor models, of substance use, 306–307, 315–316
speed congenics, 151
spinal cord minipumps, 163
spouses, socialization effects from, 517
Sprague-Dawley rats, 411, 431, 432–433
stage models, developmental trajectories, 233
startle-probe measures, 113
startle response
  as affective response, 447–448
  in humans, 377
  increases in, 444
  prepulse inhibition of, 378, 403, 430–432
  test-retest reliability of, 446–447
state laws, against genetic discrimination, 49
static clustering, *versus* dynamic clustering, 219–220, 232
statistics
  approaches to, 543–550
  combining genetic studies with, 248
  developmental phenotypes, 214–231
  modeling, 248–259, 570
  ontological knowledge in, 572
ST/b inbred mice, 154, 155, 412–413
stem cells, 151
Sternberg Memory Task, 379, 436–437
stigma, nicotine dependence as, 46–47
stochastic variable selection
  hierarchical modeling and, 547–548, 572, 573
  model selection with, 549–550, 551–552
stop-go task, 359
strain-specific differences
  aging, 170
  conditioned place preference, 158
  DNA markers, 151
  five choice serial reaction time task, 432–433
  genetic, 150
  mouse models, 153–154, 164–165, 412–413
  nicotine effects of, 135, 161, 169, 418
  nicotinic acetylcholine receptors, 172
  rat models, 411
  tolerance, 164
  unraveling of, 142
strain surveys, 422
stress, 351
  as influence, 100
  influences on, 36
  neuroendocrine response to, 354
  response mediators, 143
Stroop interference task, 379, 440, 451, 452
Stroop paradigm, 113
structural equation modeling (SEM), 248–249
  combined with latent class models, 256
  of developmental trajectories, 215
  linkage analysis and, 257–258
  for twin data, 249–257
study participants, selection of, 490–492
subcutaneous administration, 147, 172
subpopulation
  in latent class analysis, 256
  in structural equation modeling, 248–249
subPSEC (substitution position-specific evolutionary conservation), 554
substance use. *See also specific substance*
  adolescent, shared environmental influences in, 261
  age-dependent vulnerability to, 195, 198, 200–201, 212, 233–234, 292–293
  attention deficit hyperactivity disorder in, 356
  common-vulnerability model, 291–294, 306, 315–316
  dopamine in, 410, 588
  early pleasurable use, 374
  environmental factors influencing, 294–295
  interpersonal dynamics in, 522
  Iowa gambling task as predictor, 350
  modeling of, 43
  nasal spray non-response, 377
  novelty seeking in, 292–293, 348–349
  prevention of, research approaches, 294–295
  risk factors for, 340
  specific-factor models, 306–307, 315–316

substance-use comorbidity, 289–325
  association between smoking trajectories and, 296–298
  empirical examples of, 307–323, 496, 502
  future research directions, 323–324
  gender differences in, 304
  gene-environment interactions in, 320
  importance of studying, 290–292
  informative phenotypes for, 316–318, 321, 324
  literature review, 295–296
  mechanisms underlying, 291–292
  methodological issues, 321–323
  modeling, 298–307
  risk factors, 306
  two-stage models of, 323
substance-use disorders
  common *versus* specific liability to, 292–295
  diagnosis of, 291
  shared genetic risk for, 294
substitution position-specific evolutionary conservation (subPSEC), 554
subthreshold depression, 352
sucrose, 154–155, 412
support interval, 40, 42
Surgeon General's Report (1964), 24
Surgeon General's Report (1979), 24
susceptibility loci mapping, 24. *See also* candidate gene studies
sweat gland activity, 440
Swedish Twin Registry, 515
Swiss mice, 435
Swiss-Webster mice, 158, 161
switching, between trajectory groups, 255–256
systems biology, genetic association studies and, 554, 556–559
Systems Biology Markup Language (SBML), 561

T

targeted treatment, 21–22
task performance, with nicotine deprivation, 436
Taste/Sensory Processes subscale, 84
taxon, nicotine dependence as, 93–94
team sports, as protective factor, 343
temperament-based model, 343–344
test performance, definition of, 75
test-retest reliability
  acoustic startle reflex, 446–447
  ad lib smoking, 415
  diagnostic tools, 81
  event-related potential, 429
  mood effects tests, 375
  nicotine-dependence measures, 26–27, 29
  prepulse inhibition startle response, 431
thapsigargin, 167
theta rhythm (slow-wave activity), 362
TH (tyrosine hydroxylase) gene, 198–199, 269
threshold
  factor loading and, 275–276
  as "smoker," 42
time to first cigarette (TTFC)
  during adolescence, as indicator of adult nicotine dependence, 230–231
  correlations with, 90
  factor analysis of, 88–89
  nicotine metabolism association, 34
  as physical dependence measure, 79
  as quitting predictor, 80
time to maximum tolerance, 162
tissue levels of nicotine, *versus* plasma levels, 145
Tobacco Craving Questionnaire, 440
tobacco dependence, *versus* nicotine dependence, 75
tobacco industry, 24
tobacco policies, 7, 20
  effect on adolescent smoking, 193
  substance use policies and, 294–295
tobacco settlement dollars, 4
tobacco use. *See also* nicotine
  frequency of, 4, 21, 369–371, 413, 420
  history of, 27–28
  smoke compounds, 588
Tobacco Use Supplement, U.S. Census Bureau' Current Population Survey (TUS-CPS), 487, 494, 498–500
tolerance, 162–168
  genetic effects on, 146
  to repeated doses, 158
Tolerance subscale, 90–91
TPH gene, 269
trace fear conditioning, 435
transcription factor CREB, 160–161, 422
transcription factor Fosb, 161
transcription levels, alterations in, 40
transdisciplinary framework, 521
Transdisciplinary Tobacco Use Research Center (TTURC), 89, 521, 526
transitional endophenotypes, 107, 108, 200, 233
translational validation, 172

TRPC7 gene, 43
129T2/SvEmsJ mice, 431
TTFC. *See* time to first cigarette
TTURC (Transdisciplinary Tobacco Use Research Center), 89, 521, 526
TUS-CPS (Tobacco Use Supplement, U.S. Census Bureau's Current Population Survey), 487, 494, 498–500
twin studies. *See also specific study*
  adolescent smoking, 196, 259–262
  affective regulation, 446–447
  cross-substance concordance, 317, 319–320
  CYP2A6 effect, 40
  delay aversion, 351
  ecological momentary assessment, 527
  epigenetic regulation, 36
  equal environments assumption in, 516–517
  event-related potential, 428, 429
  extended family, 250–252, 262, 279, 280
  factor analysis, 88–89
  factor mixture models, 256
  genomic studies, 589
  heritability of dependence, 28–29, 86, 342, 406
  impulsivity, 451
  limitations of, 279–280
  multivariate, 252–253, 262–263
  P300 amplitude, 360
  prepulse inhibition startle response, 431
  resting EEG, 426
  smoking habits, 22, 24
  smoking initiation, 31
  structural equation modeling, 249–257
  substance-use comorbidity, 307–323, 324
  tobacco use history, 38–39
  working memory, 437
two-factor structure, 81
two-stage genetic models, initiation *versus* progression, 323
tyrosine hydroxylase *(TH)* gene, 198–199, 269

U

univariate analysis, substance-use comorbidity, 322
unmeasured genetic factors, 4, 511
upregulation, of nicotinic receptors, 135, 144–145, 588
U.S. Task Force on Community Preventive Services, 4

V

validity
  of developmental trajectory research, 234
  discriminative, 77
  predictive, 50, 90–91
variables
  independent, 495–496, 498–499
  observable, 77
  ontologies to represent knowledge about, 558–559
  perturbations from, 554
  in structural equation modeling, 248
variance
  in latent growth curve models, 254
  partitioning, 270, 280
ventral tegmental area (VTA), 152–153, 588
verapamil, 167, 168
VET (Vietnam Era Twin) Registry, 263–264
videotaped paradigms, 524
Vietnam Era Twin (VET) Registry, 263–264
vigilance, 432–434
Virginia 30,000 Study, 262
Virginia Twin Registry, 264, 269–279
  measures, 269–270
  methods, 270
  results, 270–276
  study conclusions, 276–279
  subjects, 269
Virginia Twin Study of Adolescent Behavioral Development, 260
visuospatial attention, 434
VLMR LR (Vuong-Lo-Mendell-Rubin likelihood ratio) test, 310, 312
VTA (ventral tegmental area), 152–153, 588
vulnerability
  of adolescents, 343
  differences in, 22
  modeling, 363–364
  protective factors, 87, 114
Vuong-Lo-Mendell-Rubin likelihood ratio (VLMR LR) test, 310, 312

W

Wald test, 544
watershed model, 78–79, 81–82
WCST (Wisconsin Card Sorting Test), 378, 436
Wechsler Adult Intelligence Test-Revised, 433
whole-environment scan, 530

whole-genome association studies, 4
whole-genome linkage scans, 589
whole-genome quantitative transcript screening, 170
wild-type mice
  conditioned place preference in, 159, 160, 161, 422
  in CREB activation studies, 160
  in nicotine reinforcement, 159
WinBUGS, 549
Wisconsin Card Sorting Test (WCST), 378, 436
Wisconsin Inventory of Smoking Dependence Motives (WISDM), 84–86, 85
  as assessment tool, 405
  subscales of, 90–93
Wistar rats, 425, 431, 449
withdrawal symptoms
  in adolescents, 192, 194
  cellular changes, 147
  environmental influences in, 95
  heritability of, 30
  negative affect, 443
  physical dependence inference from, 77
  physiology of, 588
  severity of, 97, 413, 447
  support interval for, 40
within-class variability, estimation of, 220–221, 233
working memory, 434–438
World Health Organization, 80–81
World Mental Health Survey Initiative, 81

X

XSEM (extended structural equation modeling), 249

Z

zygosity, function of, in substance-use phenotypes, 316–317, 320